Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer (Q35789278)

10 August 2017

1 reference

title

Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer (English)

1 reference

10 August 2017

1 reference

1 reference

A K Nowak

1

1 reference

10 August 2017

N R C Wilcken

2

1 reference

10 August 2017

M R Stockler

3

1 reference

10 August 2017

A Hamilton

4

1 reference

10 August 2017

D Ghersi

5

1 reference

10 August 2017

language of work or name

1 reference

1 June 2004

1 reference

Lancet Oncology Commission

10 August 2017

published in

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

372-380

1 reference

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901494-9

7 January 2021

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901494-9

7 January 2021

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901494-9

7 January 2021

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901494-9

7 January 2021

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901494-9

7 January 2021

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901494-9

7 January 2021

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901494-9

7 January 2021

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901494-9

7 January 2021

10.1016/S1470-2045(04)01494-9

Identifiers

DOI

1 reference

release_gswc3zlkjbfz3hfs2pnjkmgmli

10 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gswc3zlkjbfz3hfs2pnjkmgmli

24 November 2022

mapped directly with Wikidata item

1 reference